Synmosa Biopharma (4114) — Cash Flow Reinvestment Rate
Synmosa Biopharma (4114) has a Cash Flow Reinvestment Rate of 5.31x as of December 2025, reinvesting NT$986.18 Million (capex NT$59.46 Million plus investments NT$926.72 Million) from operating cash flow of NT$185.72 Million. Explore 4114 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Synmosa Biopharma Cash Flow Reinvestment Rate (2015–2025)
Historical reinvestment intensity for Synmosa Biopharma across 9 annual periods. Also explore total assets of Synmosa Biopharma for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Synmosa Biopharma (2015–2025)
Year-by-year capital reinvestment analysis for Synmosa Biopharma. For live market cap and broader valuation context, see 4114 stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.64x | NT$676.44 Million | NT$411.57 Million | NT$281.13 Million | ▲ +294.7% |
| 2024 | 0.42x | NT$325.05 Million | NT$780.62 Million | NT$269.65 Million | ▼ -78.4% |
| 2023 | 1.93x | NT$987.64 Million | NT$511.93 Million | NT$269.77 Million | ▲ +437.5% |
| 2022 | 0.36x | NT$226.22 Million | NT$630.25 Million | NT$129.29 Million | ▲ +63.6% |
| 2021 | 0.22x | NT$97.47 Million | NT$444.29 Million | NT$93.06 Million | ▼ -77.2% |
| 2020 | 0.96x | NT$244.96 Million | NT$254.40 Million | NT$154.41 Million | ▼ -97.3% |
| 2018 | 35.49x | NT$567.76 Million | NT$16.00 Million | NT$314.43 Million | ▲ +473.8% |
| 2016 | 6.19x | NT$1.46 Billion | NT$236.48 Million | NT$423.92 Million | ▼ -66.2% |
| 2015 | 18.30x | NT$431.85 Million | NT$23.60 Million | NT$369.26 Million | — |